Abstract:Background: Numerous studies have shown that glucose-6-phosphate dehydrogenase (G6PD) is a tumor-promoting factor in a variety of malignancies. However, it is not entirely clear the role and the potential molecular mechanism of G6PDH in the pathogenesis or clinical prognosis of different tumors. Methods: This study first investigated the pan-tumoral expression of G6PD, then G6PD gene expression were studied in cancers, survival prognosis, tumor immunity, immunosuppressive cell infiltration, DNA methylation, gene alteration assay, and response to immunotherapy. We also investigated the function of G6PD in the development and prognosis of various cancers. Results: Our results suggest that G6PD expression was higher in tumor tissues than in normal tissues and was related to tumor stage, metastasis, and prognosis in most cancers and subtypes of the Cancer Genome Atlas. High G6PD expression is protective in a small number of cancers, including paraganglioma, pheochromocytoma, and ovarian serous cystadenocarcinoma. However, it is a risk factor for the majority of cancers. The prognosis for progression-free survival was better in people with G6PD alterations than in those without them. G6PD and immune cell infiltration were significantly positively correlated in prostate cancer, pancreatic adenocarcinoma, liver cancer, and low-grade glioma of the brain. Additionally, the degree of G6PD methylation was shown to inversely correlate with mRNA expression. The PGD, GCLM, SRXN1, TRIM16L, and TXNRD1 genes all showed significant positive correlation with G6PD expression level. The major genetic alterations were missense mutations in G6PD, and mutations at the R192C/S locus were detected in cutaneous melanoma, uterine cancer, and thyroid carcinoma. In several malignancies, G6PD expression is associated with immunological and chemotherapeutic outcomes. Conclusions: According to the study, patients who expressed more G6PD generally had better therapeutic outcomes. Our study highlights the role of G6PD in oncogenesis, detection, prognosis, and treatment planning.

c-Src facilitates tumorigenesis by phosphorylating and activating G6PD

c-Src Promotes Tumorigenesis and Tumor Progression by Activating PFKFB3

O-GlcNAcylation of G6PD Promotes the Pentose Phosphate Pathway and Tumor Growth

C-Src Phosphorylation and Activation of Hexokinase Promotes Tumorigenesis and Metastasis

Hspb1 Enhances Sirt2-Mediated G6pd Activation And Promotes Glioma Cell Proliferation

P90 Ribosomal S6 Kinase Confers Cancer Cell Survival by Mediating Checkpoint Kinase 1 Degradation in Response to Glucose Stress

Modulation of G6PD Affects Bladder Cancer Via ROS Accumulation and the AKT Pathway in Vitro.

Glucose-6-phosphate Dehydrogenase (G6PD): the Role in Tumor Progression and Immunotherapy

G6PD promotes renal cell carcinoma proliferation through positive feedback regulation of p-STAT3

A GSTP1-mediated lactic acid signaling promotes tumorigenesis through the PPP oxidative branch

Pan-cancer analysis of G6PD carcinogenesis in human tumors.

Glucose 6-phosphate dehydrogenase is regulated through c-Src-mediated tyrosine phosphorylation in endothelial cells

Glucose-mediated N-glycosylation of RPTPα Affects Its Subcellular Localization and Src Activation.

Tyrosine Phosphorylation Activates 6-Phosphogluconate Dehydrogenase and Promotes Tumor Growth and Radiation Resistance

The P52-Zer6/g6pd Axis Alters Aerobic Glycolysis and Promotes Tumor Progression by Activating the Pentose Phosphate Pathway.

Recent findings in the regulation of G6PD and its role in diseases

The potent role of Src kinase-regulating glucose metabolism in cancer

IL-6/JAK2-dependent G6PD phosphorylation promotes nucleotide synthesis and supports tumor growth

Elevated G6PD Expression Contributes to Migration and Invasion of Hepatocellular Carcinoma Cells by Inducing Epithelial-Mesenchymal Transition

PBX3 Promotes Pentose Phosphate Pathway and Colorectal Cancer Progression by Enhancing G6PD Expression.

Activation of the NRF2 antioxidant program sensitizes tumors to G6PD inhibition